...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Current opinion in gastroenterology >Primary biliary cholangitis in China
【24h】

Primary biliary cholangitis in China

机译：中国原发性胆源性胆管炎

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Purpose of reviewPrimary biliary cholangitis (PBC) is a chronic cholestatic liver disease characterized by immunomediated destruction of small and medium-sized intrahepatic bile ducts. In 1987, a cDNA for a 74kDa mitochondrial autoantigen was cloned and identified as the E2 component of the mitochondrial pyruvate dehydrogenase complex, which improved the diagnosis and changed research directions in this field. In 1958, the first Chinese case of PBC was reported. But until 1990, a comprehensive description of the characteristics of Chinese PBC patients was published. In China we now know that PBC is not rare and usually does not progress to cirrhosis.Recent findingsThe number of Chinese patients with PBC has increased each and every year. This increase may be associated with the changes of liver disease spectrum, the application of convenient autoantibody detection kits, and the comprehensive understanding of the disease. It may also reflect, however, a westernization change in environmental features with China. There is now significant and important basic and clinical research on PBC in China, with major contributions in diagnostic criteria, treatment, and on basic biology. This has led to exciting proposals based on Chinese PBC cohorts.SummaryChinese hepatologists and scientists are now focusing their efforts on PBC. These efforts have led to new diagnostic biomarkers, novel therapeutic methods (stem cells and Chinese traditional medicine), and unique immunological mechanisms, including roles for T-follicular helper cells and monocyte subpopulations, both of which are involved in the breach of immune tolerance for PBC.
机译：复习目的原发性胆汁性胆管炎（PBC）是一种慢性胆汁淤积性肝病，其特征是免疫介导的中小型肝内胆管破坏。 1987年，克隆了一个74kDa线粒体自身抗原的cDNA，并将其鉴定为线粒体丙酮酸脱氢酶复合物的E2成分，从而改善了该领域的诊断并改变了研究方向。 1958年，中国报道了第一例中国人民银行。但直到1990年，才发表了有关中国PBC患者特征的全面描述。在中国，我们现在知道PBC并不罕见，通常不会发展为肝硬化。最新发现中国的PBC患者人数每年都在增加。这种增加可能与肝脏疾病谱的变化，便捷的自身抗体检测试剂盒的应用以及对该疾病的全面了解有关。但是，这也可能反映了中国在环境特征方面的西化变化。现在，中国对PBC进行了重要而重要的基础和临床研究，在诊断标准，治疗和基础生物学方面做出了重大贡献。这导致了基于中国人民银行队列研究的令人振奋的提议。这些努力带来了新的诊断性生物标志物，新颖的治疗方法（干细胞和中药）以及独特的免疫学机制，包括T滤泡辅助细胞和单核细胞亚群的作用，两者均参与了对T细胞的免疫耐受的破坏。中国人民银行。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号